Evidence Level:Sensitive: C2 – Inclusion Criteria
Title:
Phase IV Panitumumab Study in Indian Subjects With Metastatic Colorectal Cancer
Evidence Level:Sensitive: C2 – Inclusion Criteria
Title:
FOLFOXIRI With or Without Panitumumab in Metastatic Colorectal Cancer (VOLFI)
More C2 evidence
Evidence Level:Sensitive: C2 – Inclusion Criteria
Title:
Comparison of Two Preemptive Treatment Strategies of Panitumumab Mediated Skin Toxicity and Assessment of QoL in Patient With Ras-wt Colorectal Cancer
Evidence Level:Sensitive: C2 – Inclusion Criteria
Title:
Study to Evaluate Mechanisms of Acquired Resistance to Panitumumab
Evidence Level:Sensitive: C2 – Inclusion Criteria
Title:
Panitumumab in Combination With Radiotherapy in Patients With Locally Advanced RAS Wildtype Rectal Cancer (Clinical Stages II and III)
Evidence Level:Sensitive: C2 – Inclusion Criteria
Title:
FOLFOXIRI Plus Panitumumab in Metastatic RAS Wild-type, Left-sided Colorectal Cancer
Less C2 evidence
Evidence Level:Sensitive: C3 – Early Trials
Title:
Phase II Study of Third-Line Panitumumab Rechallenge in Patients with Metastatic Wild-Type KRAS Colorectal Cancer Who Obtained Clinical Benefit from First-Line Panitumumab-Based Chemotherapy: JACCRO CC-09
Excerpt:This study assessed the efficacy and safety of third-line panitumumab rechallenge in patients with metastatic KRAS exon 2 wild-type metastatic colorectal cancer...the 3-month PFS rate was 50.0% (95% confidence interval 30.0-70.0). The median PFS and overall survival were 3.1 months and 8.9 months, respectively. The response rate and disease control rate were 8.3% and 50.0%, respectively….Irinotecan plus panitumumab rechallenge is a promising third-line treatment regimen in patients with metastatic wild-type KRAS colorectal cancer.
DOI:10.1007/s11523-021-00845-y
Evidence Level:Sensitive: C3 – Early Trials
Title:
A phase 2 study of panitumumab with irinotecan as salvage therapy in chemorefractory KRAS exon 2 wild-type metastatic colorectal cancer patients
Excerpt:KRAS exon-2 wild-type patients failing prior irinotecan received panitumumab (6 mg/kg) and irinotecan (180 mg/m²) every 2 weeks….In this single-arm combination study, the addition of panitumumab to irinotecan in irinotecan-refractory wild-type KRAS exon-2 mCRC patients gave a 15% response rate.
DOI:https://doi.org/10.1038/s41416-019-0537-z